Weigh! G-test, the world's first liver cancer early screening product based on glycomics, entered th


2019-07-09 17:23:01

        On July 4, the signing ceremony of Shanghai Fosun Long March Medical Science Co., Ltd. and xiansida (Nanjing) Biotechnology Co., Ltd. was successfully concluded. The two sides reached a cooperation agreement on the exclusive agent of G-test oligosaccharide chain detection products of synstar, and will jointly compose a new chapter of early screening of liver cancer using G-test glycomics technology!


        There are 854000 new cases of primary liver cancer in the world every year, 466000 in China, accounting for 55% of the world's total; and there are 810000 deaths from primary liver cancer every year, 422000 in China, accounting for 52% of the world's total. The 2018 China Society of Clinical Oncology (CSCO) guidelines for the diagnosis and treatment of primary liver cancer clearly points out that primary liver cancer is the fourth common malignant tumor and the third cause of cancer death in China. It is recommended that liver ultrasound and serum AFP be used in the screening of high-risk groups to improve the cure rate of early cancer and reduce the death rate of late cancer. However, the sensitivity and specificity of ultrasound and serum AFP are not enough. About 1 / 3 of the patients with liver cancer have normal serum AFP level, especially in the early stage of liver cancer. The detection method with low sensitivity leads to the omission of curable early liver cancer.


The G-test oligosaccharide chain detection kit was approved as 'innovative medical device product' by the National Drug Administration (nmpa). G-test is based on the glycomics detection technology, through the analysis of sugar chain fingerprint to distinguish the disease status, showing excellent performance and significant advantages in the clinical research of Chinese population. The head-to-head study of G-test and AFP showed that the sensitivity of G-test was 81.82% and the performance was much higher than that of AFP (10.91%); in the patients with AFP false negative liver cancer, the sensitivity of G-test could be as high as 85.53%. The high sensitivity of G-test in patients with early liver cancer and AFP false negative liver cancer can effectively promote the early detection and treatment of liver cancer in high-risk groups such as hepatitis and cirrhosis.

Xiansida (Nanjing) Biotechnology Co., Ltd. is a Sino foreign joint venture established by Dr. Chen Cuiying, a Belgian Chinese scientist. Based on glycomics and post genomics, the company owns the glycon test technology platform with independent intellectual property rights, and is committed to the research and development of in vitro diagnostic reagents related to early cancer and physiological health status. Its founder, Dr. Chen Cuiying, once served as the project director and doctoral supervisor of scientist, senior scientist, PI project of Ghent University, Flemish Institute of biotechnology, Belgium, and won many awards such as 'the latest invention award of FFMI tumor marker in Belgium', 'Ellison Medical Foundation Award'. There is a very deep technology accumulation in the research and application of glycomics.